Synlogic (NASDAQ:SYBX) Receives News Sentiment Rating of 0.08

News stories about Synlogic (NASDAQ:SYBX) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synlogic earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.0977765770454 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Synlogic (SYBX) remained flat at $$10.45 on Monday. 9,000 shares of the company’s stock traded hands, compared to its average volume of 41,322. The company has a market cap of $170.18, a PE ratio of -1.11 and a beta of 3.17. Synlogic has a 12-month low of $8.76 and a 12-month high of $23.00.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($0.50) by ($1.16). research analysts forecast that Synlogic will post -5.42 EPS for the current fiscal year.

Several equities analysts have recently issued reports on the stock. Wedbush began coverage on shares of Synlogic in a research report on Monday, November 27th. They issued an “outperform” rating and a $20.00 target price for the company. Zacks Investment Research downgraded shares of Synlogic from a “hold” rating to a “sell” rating in a research report on Wednesday, November 22nd. Finally, Leerink Swann initiated coverage on shares of Synlogic in a research report on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $19.67.

COPYRIGHT VIOLATION NOTICE: “Synlogic (NASDAQ:SYBX) Receives News Sentiment Rating of 0.08” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/synlogic-sybx-given-daily-news-sentiment-rating-of-0-08/1818862.html.

About Synlogic

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Insider Buying and Selling by Quarter for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.